-
The first in a new class of drugs has been approved by the FDA for the treatment of diabetes mellitus. This new class of drugs decreases the renal threshold for glucose excretion by inhibiting the sodium-glucose co-transporter 2 (SGLT2), thus increasing renal clearance of glucose. Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation and marketed by Janssen Pharmaceuticals as Invokana.
-
-
Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
-
Myocardial perfusion imaging (MPI) refers to the utilization of radiotracers to image regional myocardial perfusion from coronary artery blood flow to the heart muscle. Used effectively, MPI can provide the clinician with a noninvasive technique that yields both important diagnostic and powerful prognostic information regarding the functional significance of anatomic coronary artery disease. MPI can help guide therapeutic decision-making by stratifying patients with respect to future risk for adverse outcomes.
-
-
Although widespread screening mammography has greatly increased the diagnosis of early breast cancer, it has had only a marginal effect on the diagnosis of late-stage tumors and breast cancer mortality.
-
The authors concluded that compared to beta-blockers, the risk of angioedema is highest with ACEIs or aliskiren and lowest with ARBs.
-
The authors conclude that in a large cohort of older patients with atrial fibrillation, hemorrhage is common during both the first 30 days and subsequent months of warfarin therapy, and is related to risk factors in the CHADS2 score and also to age.
-
The first inhibitor of the microsomal triglyceride transport protein (MTP) has been approved for the treatment of homozygous familial hypercholesterolemia (HoFH).
-
